Amicus Therapeutics Inc (FOLD)

Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

Zacks Investment Research

Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire Inc.

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Zacks Investment Research

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Zacks Investment Research

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024

GlobeNewswire Inc.

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

GlobeNewswire Inc.

Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?

Investing.com

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

Zacks Investment Research

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

GlobeNewswire Inc.

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

Zacks Investment Research

The Analyst Landscape: 4 Takes On Amicus Therapeutics

Benzinga

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Zacks Investment Research

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

GlobeNewswire Inc.